Joshua F. Zeidner, MD (IMAGE)
Caption
“We initially discovered this problem while treating a patient with acute promyelocytic leukemia with arsenic trioxide, a drug known to cause QT prolongation. We realized that there was inconsistent guidance about how to assess the QT interval with this drug and what values should lead to dose reductions,” said senior author Joshua F. Zeidner, MD. "The findings from this study have been practice changing as we no longer recommend the Bazett formula for clinical guidance.”
Credit
UNC LIneberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content